OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	102
Current views on lupus in children	65
Editorial introduction	54
Urticarial vasculitis	54
Giant cell arteritis: update on pathogenesis and clinical implications	45
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	42
Current approach to muscle imaging in myositis	42
Editorial introductions	32
Optimizing reproductive health management in lupus and Sjogren's syndrome	32
Osteoporosis epidemiology using international cohorts	30
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	29
Axial spondyloarthritis guidelines – aiming for maximum impact	28
Rheumatoid arthritis – the challenge of heterogeneity	28
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	28
The gut microbiota in spondyloarthritis: an update	25
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	24
Editorial introductions	24
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	24
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	23
Updates on translational and clinical research in systemic sclerosis	22
Ribosome dysfunction in osteoarthritis	22
Update on gout management: what is old and what is new	21
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	21
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	21
Editorial introduction	20

Defining and managing flares in axial spondyloarthritis	17
Editorial introductions	17
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	16
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	16
Editorial introductions	16
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	16
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	16
Epidemiology of myositis	16
Haematopoietic stem cell transplantation in paediatric rheumatic disease	16
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	16
Health inequities in the rheumatic diseases of childhood	16
Gout and the COVID-19 pandemic	15
Animal models of vasculitis	14
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	14
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	13
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	13
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	13
Biomarker discovery in psoriatic disease	12
Inflammatory back pain: a concept, not a diagnosis	12
New developments related to lung complications in pediatric rheumatic disease	11
AI am the future: artificial intelligence in pediatric rheumatology	11
Editorial introductions	11
Polymyositis: does it really exist as a distinct clinical subset?	11
Editorial introductions	11
Insights into origins and specificities of autoantibodies in systemic sclerosis	11
Diagnosis and management of primary heart involvement in systemic sclerosis	10
Insights into the molecular landscape of osteoarthritis in human tissues	10
Investigating gout flares: beyond a definition	10
Heart involvement in systemic sclerosis: emerging concepts	10
Exploring challenges in the management and treatment of inclusion body myositis	10
Editorial introduction	10
Emerging biologic therapies for systemic lupus erythematosus	10
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	9
Animal models in systemic sclerosis: an update	9
The association of Behçet's syndrome with HLA-B51 as understood in 2021	9
The contribution of endothelial cells to tissue fibrosis	9
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	9
Epidemiology of osteoarthritis: literature update 2022–2023	9
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	9
Current management of giant cell arteritis and its complications	9
Vasculitis and the NLRP3 inflammasome	9
Management of postinfectious inflammatory arthritis	9
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	8
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	8
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	8
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	8
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	8
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	8
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	8

New therapies in anti-MDA5 antibody-positive dermatomyositis	8
Calcinosis in systemic sclerosis	7
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	7
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	7
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	7
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	7
Clinical endpoints in myositis: challenges and ways forward	7
Takayasu arteritis	6
Osteoarthritis gene therapy in 2022	6
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	6
Safety updates in novel therapeutics for pediatric rheumatic disease	6
Contribution of keratinocytes to dermal fibrosis	6
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	6
Bone in osteoarthritis: imaging and interventions	6
What are mice teaching us about psoriatic arthritis?	6
Update on muscle imaging in myositis	6
Quo vadis reactive arthritis?	5
Go or no-go for treat-to-target in axial spondyloarthritis?	5
Renal disease in pediatric rheumatology	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Epidemiology of systemic vasculitis	5
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	5
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	5
Should CAR-T cells be used as monotherapy?	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Recent advances in immunometabolism in rheumatic diseases	5
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	5
Metabolic perturbations in systemic sclerosis	5
The impact of the COVID-19 pandemic on the field of pediatric rheumatology	5
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	5
Calcinosis in systemic sclerosis	4
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	4
Editorial introductions	4
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	4
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	4
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	4
Omics studies in Behçet's disease	4
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease	4
Differential diagnosis of necrotizing myopathy	3
Disease modification in axial spondyloarthritis – still a controversy?	3
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	3
Regulatory T cells and systemic vasculitis	3
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	3
Vaccination updates and special considerations for systemic lupus erythematosus patients	3
Editorial introduction	3
Advances in osteoarthritis imaging	3
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	3
Methods for objective assessment of skin involvement in systemic sclerosis	3
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	3
Editorial myositis and myopathies	3
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition	3
Editorial introduction	3
Drug therapy in juvenile spondyloarthritis	3
Intestinal dysbiosis in spondyloarthritis – chicken or egg?	3
Is osteoarthritis a mitochondrial disease? What is the evidence	3
New molecular targets in the treatment of rheumatoid arthritis	2
An update on inflammation in antiphospholipid syndrome	2
Understanding psoriatic disease at single-cell resolution: an update	2
SGLT-2 inhibitors: new horizons for rheumatologists	2
Human genetics of Whipple's disease	2
A treat-to-target approach is needed for Behçet's syndrome	2
Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?	2
An update on topical therapies for psoriasis	2
The impact of omics research on our understanding of osteoarthritis and future treatments	2
Novel therapies in juvenile idiopathic arthritis	2
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	2
Editorial introductions	2
The role of immunomodulatory medications in the treatment of COVID-19	2
Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis	2
Rheumatologic immune checkpoint inhibitor-related adverse events	2
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	2
Physical exercise for the management of systemic autoimmune myopathies: recent findings, and future perspectives	2
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	2
Integrating genetic and social factors to understand health disparities in lupus	2
Educational needs and challenges in axial spondyloarthritis	2